IDELALISIB MONOTHERAPY RESULTS IN DURABLE RESPONSES IN PATIENTS WITH RELAPSED OR REFRACTORY WALDENSTROM'S MACROGLOBULINEMIA (WM)

被引：0
|
作者：
Coutre, S. [1 ]
Leonard, J. [2 ]
Flowers, C. [3 ]
Davies, A. [4 ]
Jurczak, W. [5 ]
Byrd, J. [6 ]
Spurgeon, S. [7 ]
Peterman, S.
Holes, L. [8 ]
Cho, Y. [8 ]
Sorenson, B. [8 ]
Godfrey, W. [8 ]
Gopal, A. [9 ]
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Weill Cornell Med Ctr, New York, NY USA
[3] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[4] Southampton Gen Hosp, Southampton SO9 4XY, Hants, England
[5] Malopolskie Ctr Med SC, Krakow, Poland
[6] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[7] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[8] Gilead Sci Inc, Foster City, CA 94404 USA
[9] Univ Washington, Sch Med, Seattle, WA USA
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P690
引用
收藏
页码：273 / 273
页数：1
相关论文
共 50 条
  • [21] Final Results of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed and/or Refractory Waldenstrom Macroglobulinemia (WM).
    Ghobrial, Irene M.
    Leleu, Xavier
    Rubin, Nancy
    Xie, Wanling
    Hong, Fangxin
    Chuma, Stacey
    Leduc, Renee
    Nelson, Marybeth
    O'Connor, Kelly
    Sam, Amy
    Harris, Brianna
    Warren, Diane
    Sportelli, Peter
    Treon, Steven P.
    Weller, Edie
    Anderson, Kenneth C.
    Richardson, Paul G.
    BLOOD, 2008, 112 (11) : 372 - 372
  • [22] Treatment free remission (TFR) and overall response rate (ORR) results in patients with relapsed/refractory Waldenstrom's macroglobulinemia (WM) treated with CLR 131.
    Ailawadhi, Sikander
    Chanan-Khan, Asher Alban Akmal
    Peterson, Jennifer Layton
    Longcor, Jarrod
    Oliver, Katherine
    Brown, Matthew Francis
    Friend, John
    Green, Damian Jonathan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia
    Gertz, MA
    Geyer, SM
    Badros, A
    Kahl, BS
    Erlichman, C
    CLINICAL LYMPHOMA, 2005, 5 (04): : 282 - 284
  • [24] Activity of alemtuzumab (Mabcampath) in relapsed/refractory Waldenstrom's macroglobulinemia.
    Owen, RG
    Rawstron, AC
    Osterborg, A
    Lundin, J
    Svensson, G
    Hillmen, P
    BLOOD, 2003, 102 (11) : 644A - 645A
  • [25] Perifosine: Final Results of a Phase II Trial in Relapsed/Refractory Waldenstrom Macroglobulinemia
    Ghobrial, I. M.
    Roccaro, A. M.
    Sportelli, P.
    Treon, S. P.
    Weller, E.
    Leleu, X.
    Rubin, N.
    Hong, F.
    Leduc, R.
    Chuma, S.
    Nelson, M.
    C'Connor, K.
    Sam, A.
    Harris, B.
    Warren, D.
    Anderson, K. C.
    Richardson, P. G.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S83 - S83
  • [26] Waldenstrom's macroglobulinemia (WM) in Japan. Results of a retrospective survey
    Toumilhac, O.
    Kumagawa, N.
    Ishitsuka, K.
    Morel, P.
    Tamura, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 224 - 224
  • [27] Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM)
    Ghobrial, I. M.
    Leleu, X.
    Rubin, N.
    Leduc, R.
    Chuma, S.
    Nelson, M.
    Sportelli, P.
    Richardson, P. G.
    Treon, S. P.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [28] Outcomes of young patients with Waldenstrom macroglobulinemia (WM).
    Vallumsetla, Nishanth
    Paludo, Jonas
    Ansell, Stephen Maxted
    Gertz, Morie A.
    Dispenzieri, Angela
    Lacy, Martha
    Buadi, Francis
    Dingli, David
    Hayman, Suzanne R.
    Go, Ronald S.
    Kyle, Robert A.
    Rajkumar, Vincent
    Kumar, Shaji
    Kapoor, Prashant
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Report of consensus panel 2 from the 11th international workshop on Waldenstrom's macroglobulinemia on the management of relapsed or refractory WM patients
    D'Sa, S.
    Matous, J., V
    Advani, R.
    Buske, C.
    Castillo, J. J.
    Gatt, M.
    Kapoor, P.
    Kersten, M. J.
    Leblond, V
    Leiba, M.
    Palomba, M. L.
    Paludo, J.
    Qiu, L.
    Sarosiek, S.
    Shadman, M.
    Talaulikar, D.
    Tam, C. S.
    Tedeschi, A.
    Thomas, S. K.
    Tohidi-Esfahani, I
    Trotman, J.
    Varettoni, M.
    Vos, J. M., I
    Garcia-Sanz, R.
    San-Miguel, J.
    Dimopoulos, M. A.
    Treon, S. P.
    Kastritis, E.
    SEMINARS IN HEMATOLOGY, 2023, 60 (02) : 80 - 89
  • [30] Acalabrutinib in Patients (pts) with Waldenstrom Macroglobulinemia (WM)
    Owen, Roger
    McCarthy, Helen
    Rule, Simon
    D'Sa, Shirley
    Thomas, Sheeba
    Forconi, Francesco
    Anderson, Thomas
    Kersten, Marie Jose
    Zinzani, Pier Luigi
    Iyengar, Sunil
    Kothari, Jaimal
    Minnema, Monique
    Kastritis, Efstathios
    Izumi, Raquel
    Slatter, J. Greg
    Mittag, Diana
    Wei, Helen
    Chen, Dih-Yin
    Patel, Priti
    Furman, Richard R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S285 - S286
12345